1
|
Jelicic J, Stauffer Larsen T, Bukumiric Z, Andjelic B. The clinical applicability of current prognostic models in follicular lymphoma: A systematic review. Crit Rev Oncol Hematol 2021; 164:103418. [PMID: 34246773 DOI: 10.1016/j.critrevonc.2021.103418] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Revised: 06/18/2021] [Accepted: 07/04/2021] [Indexed: 12/29/2022] Open
Abstract
The Follicular Lymphoma International Prognostic Index (FLIPI) is widely used for risk stratification of patients with follicular lymphoma (FL). Motivated by evolvement in treatment modalities, several prognostic models for FL have been proposed recently. This systematic review aimed to identify available prognostic models for newly diagnosed FL and discuss their potential limitations. A total of ten studies fulfilled the inclusion criteria. Different clinical, laboratory, radiological, and histopathological findings were combined in prognostic models. The majority of studies developed models from clinical trial cohorts, and most lacked validation in populations treated with current treatment options. Although the FLIPI is the most widely used model for prognostication in FL patients, current prognostic models, including FLIPI, are rarely used in clinical practice for treatment decision-making. Future studies should validate the existing, or develop new prognostic models, to identify which of the current standard treatment options benefit high-risk FL patients the most.
Collapse
Affiliation(s)
- Jelena Jelicic
- Department of Hematology, Odense University Hospital, Odense, Denmark
| | - Thomas Stauffer Larsen
- Department of Hematology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
| | - Zoran Bukumiric
- Department of Statistics, Faculty of Medicine, University of Belgrade, Belgrade, Serbia
| | - Bosko Andjelic
- Department of Haematology, Blackpool Victoria Hospital, Lancashire Haematology Centre, Blackpool, United Kingdom
| |
Collapse
|
2
|
Mozas P, Rivero A, López-Guillermo A. Past, present and future of prognostic scores in follicular lymphoma. Blood Rev 2021; 50:100865. [PMID: 34187710 DOI: 10.1016/j.blre.2021.100865] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2021] [Revised: 06/17/2021] [Accepted: 06/21/2021] [Indexed: 12/11/2022]
Abstract
Although most follicular lymphoma (FL) patients have prolonged survival, the identification of those at risk of early progression, multiple relapses or histological transformation is essential for the improvement of long-term outcomes. In this sense, a plethora of prognostic indexes have been developed in the last decades. However, determining which one is more accurate and clinically meaningful remains a challenge. Key factors for the external validity of available indexes include characteristics of the study population, treatment intervention, and design of the study. While initial risk scores were composed of clinical, biochemical, and hematological variables, genomic and imaging data have been incorporated in recent years. Despite an obvious step forward in the knowledge of the natural history and biology of FL, predictions remain inaccurate. Further research will likely incorporate information from circulating tumor DNA and artificial intelligence models to refine the prognostic classification of the heterogeneous FL population.
Collapse
Affiliation(s)
- Pablo Mozas
- Department of Hematology, Hospital Clínic de Barcelona, Barcelona, Spain.
| | - Andrea Rivero
- Department of Hematology, Hospital Clínic de Barcelona, Barcelona, Spain
| | | |
Collapse
|
3
|
Cánovas A, Alonso JJ, Barreiro G, Aguirre C. Prognostic Factors in Follicular Lymphoma: The Importance of beta-2 Microglobulin. TUMORI JOURNAL 2018; 96:117-21. [DOI: 10.1177/030089161009600119] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Aims and background The Follicular Lymphoma International Prognostic Index (FLIPI) is a useful tool for the prognostic assessment of follicular lymphoma but beta-2 microglobulin (B2M) was not incorporated in this index. We aimed to compare the predictive value of B2M, FLIPI and other prognostic factors not included in the FLIPI index for overall survival (OS), complete remission (CR), and time to treatment failure (TTF) in a nonselected follicular lymphoma series. Methods and study design Retrospective univariate and multivariate analysis of the prognostic value (for OS, CR, TTF) of B2M, FLIPI and other prognostic variables in follicular lymphoma was conducted in a cohort of follicular lymphoma patients between 1987 and 2007. Results One hundred and six patients were studied. In univariate analysis B2M and B symptoms were significantly associated with OS, and FLIPI only detected two risk levels. In multivariate analysis of OS only two significant variables were found: FLIPI and B2M. Multivariate analysis of CR showed that normal B2M, absence of a bulky mass, uninvolved bone marrow, and chemotherapy with rituximab were significant predictors of CR. FLIPI (three levels), B2M, bone marrow infiltration, and chemotherapy with rituximab were significantly associated with TTF. Conclusions We found a high predictive value of B2M for OS, CR, and TTF. B2M and FLIPI were the most important variables to predict OS. However, in our series FLIPI differentiated only between two mortality risk levels.
Collapse
Affiliation(s)
- Araceli Cánovas
- Department of Internal Medicine, Hospital de Cruces, Faculty of Medicine (UPV) Baracaldo, Vizcaya, Spain
| | - Juan J Alonso
- Department of Internal Medicine, Hospital de Cruces, Faculty of Medicine (UPV) Baracaldo, Vizcaya, Spain
| | - Guillermo Barreiro
- Department of Internal Medicine, Hospital de Cruces, Faculty of Medicine (UPV) Baracaldo, Vizcaya, Spain
| | - Ciriaco Aguirre
- Department of Internal Medicine, Hospital de Cruces, Faculty of Medicine (UPV) Baracaldo, Vizcaya, Spain
| |
Collapse
|
4
|
Sorigue M, Sancho JM. Current prognostic and predictive factors in follicular lymphoma. Ann Hematol 2017; 97:209-227. [PMID: 29032510 DOI: 10.1007/s00277-017-3154-z] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2017] [Accepted: 10/09/2017] [Indexed: 12/27/2022]
Abstract
Follicular lymphoma (FL) is generally considered an indolent disorder. With modern day treatments, long remissions are often achieved both in the front-line and relapsed setting. However, a subset of patients has a more aggressive course and a worse outcome. Their identification is the main purpose of modern day prognostic tools. In this review, we attempt to summarize the evidence concerning prognostic and predictive factors in FL, including (1) pre-treatment factors, from baseline clinical characteristics and imaging tests to histological grade, the microenvironment and genomic abnormalities; (2) post-treatment factors, i.e., depth of response, measured both by imaging tests and minimal residual disease; (3) factors at relapse and duration of response; and (4) prognostic factors in histological transformation. We conclude that, despite the existence of numerous tools, the availability of some of them is still limited; they generally suffer from notable downsides, and most have unproven predictive value, thus having scarce bearing on the choice of regimen at present. However, with the technological and scientific developments of the last few years, the potential for these prognostic factors is promising, particularly in combination, which will probably, in time, help guide therapeutic decisions.
Collapse
MESH Headings
- Antineoplastic Combined Chemotherapy Protocols
- Bone Marrow/drug effects
- Bone Marrow/metabolism
- Bone Marrow/pathology
- Chromosomes, Human, Pair 14/chemistry
- Chromosomes, Human, Pair 18/chemistry
- Clinical Trials as Topic
- Disease-Free Survival
- Humans
- Lymphoma, Follicular/diagnostic imaging
- Lymphoma, Follicular/drug therapy
- Lymphoma, Follicular/genetics
- Lymphoma, Follicular/mortality
- Mutation
- Neoplasm Grading
- Neoplasm, Residual/diagnostic imaging
- Neoplasm, Residual/drug therapy
- Neoplasm, Residual/genetics
- Neoplasm, Residual/mortality
- Positron-Emission Tomography
- Prognosis
- Recurrence
- Risk Factors
- Translocation, Genetic
- Tumor Suppressor Protein p53/genetics
- Tumor Suppressor Protein p53/metabolism
Collapse
Affiliation(s)
- Marc Sorigue
- Department of Hematology, ICO-Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras, Universitat Autònoma de Barcelona, Ctra. Canyet, 08916, Badalona, Spain.
| | - Juan-Manuel Sancho
- Department of Hematology, ICO-Hospital Germans Trias i Pujol, Institut de Recerca Josep Carreras, Universitat Autònoma de Barcelona, Ctra. Canyet, 08916, Badalona, Spain
| |
Collapse
|
5
|
Systemic Front Line Therapy of Follicular Lymphoma: When, to Whom and How. Mediterr J Hematol Infect Dis 2016; 8:e2016062. [PMID: 27872742 PMCID: PMC5111519 DOI: 10.4084/mjhid.2016.062] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2016] [Accepted: 11/04/2016] [Indexed: 02/06/2023] Open
Abstract
The natural history of follicular lymphoma is usually characterized by an indolent course with a high response rate to the first line therapy followed by recurrent relapses, with a time to next treatment becoming shorter after each subsequent treatment line. More than 80% of patients have advanced stage disease at diagnosis. The time of initiation and the nature of the treatment is mainly conditioned by symptoms, tumor burden, lymphoma grading, co-morbidities and patients preference. A number of clinical and biological factors have been determined to be prognostic in this disease, but the majority of them could not show to be predictive of response to treatment, and therefore can’t be used to guide the treatment choice. CD20 expression is the only predictive factor recognized in the treatment of FL and justifies the use of “naked” or “conjugated” anti-CD20 monoclonal antibodies as a single agent or in combination with chemo- or targeted therapy. Nevertheless, as this marker is almost universally found in FL, it has little role in the choice of treatment. The outcome of patients with FL improved significantly in the last years, mainly due to the widespread use of rituximab, autologous and allogeneic transplantation in young and fit relapsed patients, the introduction of new drugs and the improvement in diagnostic accuracy and management of side effects. Agents as new monoclonal antibodies, immuno-modulating drugs, and target therapy have recently been developed and approved for the relapsed setting, while studies to evaluate their role in first line treatment are still ongoing. Here we report our considerations on first line treatment approach and on the potential factors which could help in the choice of therapy.
Collapse
|
6
|
Supari D, Ananthamurthy A. Nodal Follicular Lymphomas: A Clinicopathological Study from a Tertiary Care Centre in South India. Indian J Hematol Blood Transfus 2016; 32:182-5. [PMID: 27065580 DOI: 10.1007/s12288-015-0610-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2015] [Accepted: 10/19/2015] [Indexed: 11/27/2022] Open
Abstract
The aim of this study was to assess the distribution of nodal follicular lymphomas (FL) among various subtypes of non- Hodgkin lymphoma and to study their clinico-pathological features. Clinical details, histomorphology including grading & patterns and immunoprofile of 44 cases were studied. Majority of the cases were grade 1 (61 %) FL. BCL2 positivity was higher in low grade FLs (97 %). An associated diffuse large B cell lymphoma component was seen in 18 % and was present only in conjunction with grade 3 FL. Majority of our patients (76 %) had a high FLIPI score and belonged to the high risk group. Our study showed that the incidence of FLs is much lower in the Indian population (14.5 %) when compared to western studies and majority were of low grade. Although there was complete initial response to treatment, relapse was common and was much higher in low grade FLs with diffuse areas on histology, Ann Arbor stage III/IV and FLIPI scores of 3-5.
Collapse
Affiliation(s)
- Divya Supari
- St John's Medical College, Sarjapur Road, Bangalore, 560034 India
| | | |
Collapse
|
7
|
Sancho JM, García O, Mercadal S, Pomares H, Fernández-Alvarez R, González-Barca E, Tapia G, González-García E, Moreno M, Domingo-Domènech E, Sorigué M, Navarro JT, Motlló C, Fernández-de-Sevilla A, Feliu E, Ribera JM. The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment. Leuk Res 2015; 39:853-8. [DOI: 10.1016/j.leukres.2015.05.009] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2015] [Revised: 05/21/2015] [Accepted: 05/22/2015] [Indexed: 10/23/2022]
|
8
|
Kritharis A, Sharma J, Evens AM. Current therapeutic strategies and new treatment paradigms for follicular lymphoma. Cancer Treat Res 2015; 165:197-226. [PMID: 25655611 DOI: 10.1007/978-3-319-13150-4_8] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
Follicular lymphoma (FL) is an indolent non-Hodgkin's lymphoma that remains an incurable disease for most patients. It is responsive to a variety of different treatments, however it follows a pattern of relapsing and remitting disease. Traditional therapeutic options for patients with untreated FL include expectant observation for asymptomatic and low tumor burden and multiagent cytotoxic chemotherapy for symptomatic and/or high tumor burden. Biologics have become an integral part of therapy with agents that target B lymphocytes, including monoclonal anti-CD20 antibodies and radiolabeled anti-CD20 antibodies. Treatment response to cytotoxic and biologic therapy is high initially; however, with subsequent treatments, response rate and remission duration typically decline and cumulative toxicities increase. The identification of novel targeted agents, use of stem cell transplantation, and new treatment combinations provide the opportunity to enhance patient outcomes. In this review, we critically examine standard treatment strategies for patients with newly diagnosed and relapsed or refractory FL and discuss established and emerging novel therapeutic approaches.
Collapse
Affiliation(s)
- Athena Kritharis
- Tufts Medical Center, 800 Washington Street, Boston, MA, 02111, USA
| | | | | |
Collapse
|
9
|
Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. Blood 2014; 125:992-8. [PMID: 25422100 DOI: 10.1182/blood-2014-06-583369] [Citation(s) in RCA: 41] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Serum cytokines and chemokines may reflect tumor biology and host response in follicular lymphoma (FL). To determine whether the addition of these biological factors may further refine prognostication, 30 cytokines and chemokines were measured in pretreatment serum specimens from newly diagnosed FL patients (n = 209) and from 400 matched controls. Cytokine levels were correlated with clinical outcome in patients who were observed or received single agent rituximab, or those who received chemotherapy. Correlations with outcome in chemotherapy treated patients were further examined in a separate cohort of 183 South West Oncology Group (SWOG) patients and all patients were then included in a meta-analysis. Six cytokines were associated with outcome in the Molecular Epidemiology Resource (MER) after adjusting for the FL international prognostic index. In patients who were observed or treated with rituximab alone, increased serum IL-12 and interleukin 1 receptor antagonist (IL-1RA) (P = .005 and .02) were associated with a shorter event-free survival. In patients receiving chemotherapy, hepatocyte growth factor, IL-8, IL-1RA, and CXCL9 (P = .015, .048, .004, and .0005) predicted a shorter EFS. When the MER chemotherapy treated patients and SWOG patients were combined in a meta-analysis, IL-2R, IL-1RA, and CXCL9 (P = .013, .042, and .0012) were associated with a poor EFS.
Collapse
|
10
|
Early stage W.H.O. grade I and II follicular lymphoma treated with radiation therapy alone. PLoS One 2013; 8:e65156. [PMID: 23762303 PMCID: PMC3675117 DOI: 10.1371/journal.pone.0065156] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2013] [Accepted: 04/21/2013] [Indexed: 11/19/2022] Open
Abstract
Objectives This retrospective study was undertaken to evaluate the outcome of patients with stage I or II (limited stage), grade I–II follicular non-Hodgkin’s lymphoma (FL) treated with radiation therapy (RT) alone as initial management. Methods Patients with stage I or II and pathologically confirmed WHO grade I or II FL treated initially with RT alone between 1982 and 2008 were identified from a population based cancer registry. Results Forty patients with a mean age 61.3 years at diagnosis were identified. The median follow up was 6.9 years from the end of radiation therapy. Stage was I (n = 26) and II (n = 14). None had B symptoms. The Follicular Lymphoma International Prognostic Index (FLIPI) was low risk in 26 patients and intermediate risk in 5. Doses ranged from 15 Gy to 48 Gy, with a median dose of 35 Gy. All patients achieved a complete clinical response (CR). 5 and 10 year overall survival (OS) was 86% and 59%, progression free survival (PFS) 67% and 54%. Age ≥60 at diagnosis was associated with reduced OS, p = 0.029, but did not affect PFS. No other clinical features including grade or FLIPI were significant for outcomes. Local failure was uncommon occurring in 8% (3/40) although this was 21% (3/14) of all recurrences. Conclusions OS and PFS outcomes for radiation alone in limited stage low grade FL patients from this single institution study are consistent with previously published data. No predictors were prognostic for PFS. A dose of ≤35 Gy may be appropriate. In this highly selected homogeneous group the FLIPI loses discriminating ability. Local control is excellent, and a majority of patients are free of disease after 5 years.
Collapse
|
11
|
Bains P, Al Tourah A, Campbell BA, Pickles T, Gascoyne RD, Connors JM, Savage KJ. Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy. Ann Oncol 2013; 24:428-432. [PMID: 23035152 DOI: 10.1093/annonc/mds433] [Citation(s) in RCA: 35] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/07/2023] Open
Abstract
BACKGROUND The established treatment of limited-stage follicular lymphoma is radiotherapy (RT). There is an inherent risk of transformation of follicular lymphoma to aggressive lymphoma; however, the frequency and impact on the outcome are unknown in limited-stage patients. MATERIALS AND METHODS We identified 237 patients with limited-stage follicular lymphoma treated with curative intent RT. Cases were reviewed to determine the frequency of transformation and subsequent survival. RESULTS With a median follow-up of 7.4 years, the 10-year risk of transformation was 18.5%. With a median follow-up after transformation of 4.7 years, the 3-year post-transformation progression-free survival (PFS) and overall survival (OS) were 42% and 44%, respectively. The addition of rituximab improved the 3-year post-transformation PFS and OS compared with combination chemotherapy alone (78% versus 15%, P < 0.00001) and (87% versus 38.5%, P < 0.00001), respectively. In multivariate analysis, only rituximab was associated with OS [HR 0.07 (95% CI 0.015-0.312, P = 0.001)] and PFS [HR 0.19 (95% CI 0.55-0.626, P = 0.007)] following transformation. CONCLUSIONS There is a moderate risk of transformation in limited-stage follicular lymphoma treated with curative intent RT, and it substantially impacts outcome in these patients. Treatment with rituximab at the time of transformation appears to improve survival in this otherwise poor-risk population.
Collapse
MESH Headings
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Murine-Derived/adverse effects
- Antibodies, Monoclonal, Murine-Derived/therapeutic use
- Cell Transformation, Neoplastic
- Combined Modality Therapy
- Disease-Free Survival
- Female
- Humans
- Lymphoma, Follicular/drug therapy
- Lymphoma, Follicular/mortality
- Lymphoma, Follicular/pathology
- Lymphoma, Follicular/radiotherapy
- Male
- Middle Aged
- Rituximab
- Survival
- Treatment Outcome
Collapse
Affiliation(s)
- P Bains
- Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver; Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada
| | - A Al Tourah
- Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver; Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada
| | - B A Campbell
- Department of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Australia
| | - T Pickles
- Department of Radiation Oncology, British Columbia Cancer Agency, Vancouver
| | - R D Gascoyne
- Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver; Department of Pathology and the Centre for Lymphoid Cancer, British Columbia Cancer Agency Vancouver, Canada
| | - J M Connors
- Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada
| | - K J Savage
- Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver; Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, Canada.
| |
Collapse
|
12
|
Smith SM. Dissecting follicular lymphoma: high versus low risk. HEMATOLOGY. AMERICAN SOCIETY OF HEMATOLOGY. EDUCATION PROGRAM 2013; 2013:561-567. [PMID: 24319232 DOI: 10.1182/asheducation-2013.1.561] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Progress in the management of follicular lymphoma (FL) has translated to improved outcomes, with most patients surviving a decade or more from the time of diagnosis. However, the disease remains quite heterogeneous and a substantial number of patients have more aggressive disease with short responses to therapy and/or transformation to higher-grade lymphomas. Given the lack of a single standard approach, it is important to understand sources of heterogeneity among patients that influence initial management, surveillance strategies, and overall prognosis. Most of the validated tools, such as the Follicular Lymphoma International Prognostic Index (FLIPI) and FLIPI-2, apply to the frontline setting, and there is an unmet need for prognostic tools in relapsed and refractory disease states. In particular, the number of prior treatment regimens may be less important than the duration of response to the most recent regimen and the type of prior therapy received. Furthermore, despite awareness of progressive genetic and epigenetic derangements and a growing appreciation of the microenvironment's role in FL outcomes, there is no validated means of incorporating biologic data into clinical prognostic indices. This review highlights the current state of knowledge regarding risk stratification in FL.
Collapse
Affiliation(s)
- Sonali M Smith
- 1Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL
| |
Collapse
|
13
|
Arthur FKN, Owusu L, Yeboah FA, Rettig T, Osei-Akoto A. Prognostic significance of biochemical markers in African Burkitt's lymphoma. Clin Transl Oncol 2012; 13:731-6. [PMID: 21975335 DOI: 10.1007/s12094-011-0724-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/15/2022]
Abstract
BACKGROUND AND PURPOSE Endemic Burkitt's lymphoma (eBL) remains the prevalent form of paediatric cancer in tropical Africa with subtle pathological differences. This calls for intensified efforts to validate the global prognostic markers within local settings for improved cancer treatment and survival. This study proposes prognostic markers for enhanced eBL treatment and management. PATIENTS AND METHOD One hundred and eighty histologically and/or clinically diagnosed BL patients at Komfo Anokye Teaching Hospital, Kumasi, Ghana were eligible for this cross-sectional eight-year retrospective study. Biochemical, clinical and demographic data, before chemotherapy administration, were documented and examined for their progression-free (PFS) and overall survival (OS) significance. RESULTS A mean age of 6 (SD=2.7, range: 1-16) years was observed with general male dominance (M:F=1.69:1). Total serum lactate dehydrogenase (HR=2.04; 95% CI, 1.25-3.32; log rank=8.3; p=0.004), serum creatinine (HR=3.59; 95% CI, 1.62-7.98; log rank=15.4; p=0.002) and St. Jude stage (HR=1.74; 95% CI, 1.11-2.73; log rank=8.0; p=0.015) were important independent prognostic biochemical markers for both PFS and OS. Age, serum calcium, uric acid, potassium, sodium and phosphorus were non-prognostic. CONCLUSION The better monitoring of these prognostic indices coupled with risk-stratification treatment may improve patients' survival, especially in resource-limited settings.
Collapse
Affiliation(s)
- F K N Arthur
- Department of Biochemistry and Biotechnology, College of Science, Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana
| | | | | | | | | |
Collapse
|
14
|
McNamara C, Davies J, Dyer M, Hoskin P, Illidge T, Lyttelton M, Marcus R, Montoto S, Ramsay A, Wong WL, Ardeshna K. Guidelines on the investigation and management of follicular lymphoma. Br J Haematol 2011; 156:446-67. [PMID: 22211428 DOI: 10.1111/j.1365-2141.2011.08969.x] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
15
|
Abstract
Limited stage (I-II) follicular lymphoma is an uncommon entity, since most patients with this disease have generalized adenopathy (stage III) or bone marrow involvement (stage IV). Although patients who present with stage III-IV disease often are considered to be incurable, ~50% of patients with limited disease will enjoy long-term freedom-from progression, usually following treatment with radiation therapy. Relapse among these patients is uncommon after 10 years and exceedingly rare after 15 years. Radiation treatment is generally restricted to the involved nodal region(s) with modest (~5 cm.) extension proximally and distally. Radiation dose is generally 30 Gy, but may be boosted slightly (36 Gy total) in the presence of bulky disease. Randomized clinical trials have been insufficiently powered to define the value of any additional treatment beyond radiation therapy, although single arm studies suggest a benefit to the addition of chemotherapy. There have been no reported experiences with chemo-immunotherapy or radioimmunotherapy. Patients should be monitored during follow up to identify transformation to a more aggressive lymphoma.
Collapse
Affiliation(s)
- Richard T Hoppe
- Department of Radiation Oncology, 875 Blake Wilbur Drive, Room CC-G224, Stanford University, Stanford, CA 94305, USA.
| |
Collapse
|
16
|
van de Schans S, Steyerberg E, Nijziel M, Creemers GJ, Janssen-Heijnen M, van Spronsen D. Validation, revision and extension of the Follicular Lymphoma International Prognostic Index (FLIPI) in a population-based setting. Ann Oncol 2009; 20:1697-702. [DOI: 10.1093/annonc/mdp053] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Buske C, Gisselbrecht C, Gribben J, Letai T, Mclaughlin P, Wilson W. Refining the treatment of follicular lymphoma. Leuk Lymphoma 2009; 49 Suppl 1:18-26. [DOI: 10.1080/10428190802311409] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
18
|
Díaz-Alderete A, Doval A, Camacho F, Verde L, Sabin P, Arranz-Sáez R, Bellas C, Corbacho C, Gil J, Perez-Martín M, Ruiz-Marcellán M, Gonzalez L, Montalbán C, Piris M, Menarguez J. Frequency ofBCL2andBCL6translocations in follicular lymphoma: Relation with histological and clinical features. Leuk Lymphoma 2009; 49:95-101. [DOI: 10.1080/10428190701742472] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
19
|
Low stage follicular lymphoma: biologic and clinical characterization according to nodal or extranodal primary origin. Am J Surg Pathol 2009; 33:591-8. [PMID: 19065102 DOI: 10.1097/pas.0b013e31818e6489] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Studies suggest that primary extranodal follicular lymphoma (FL) is not infrequent but it remains poorly characterized with variable histologic, molecular, and clinical outcome findings. We compared 27 extranodal FL to 44 nodal FL using morphologic, immunohistochemical, and molecular genetic techniques and evaluated the clinical outcome of these 2 similarly staged groups. Eight cases of primary cutaneous follicle center lymphoma were also studied. In comparison to nodal FL, a greater number of extranodal FL contained a diffuse growth pattern (P=0.004) and lacked CD10 expression (P=0.014). Fifty-four percent of extranodal and 42% of nodal FL cases showed evidence of t(14;18), with minor breakpoints (icr, 3'BCL2, 5'mcr) more commonly found in extranodal cases (P=0.003). Outcome data showed no significant differences in overall survival (P=0.565) and progression-free survival (P=0.627) among extranodal, nodal, and primary cutaneous follicle center lymphoma cases. Analysis of all cases by t(14;18) status indicate that the translocation-negative group is characterized by a diffuse growth pattern (P=0.043) and lower BCL2 expression (P=0.018). The t(14;18)-positive group showed significantly better overall survival (P=0.019) and disease-specific survival (P=0.006) in comparison with the t(14;18)-negative group. In low stage FL, the status of t(14;18) seems to be more predictive of outcome than origin from an extranodal versus nodal site.
Collapse
|
20
|
Friedberg JW, Taylor MD, Cerhan JR, Flowers CR, Dillon H, Farber CM, Rogers ES, Hainsworth JD, Wong EK, Vose JM, Zelenetz AD, Link BK. Follicular lymphoma in the United States: first report of the national LymphoCare study. J Clin Oncol 2009; 27:1202-8. [PMID: 19204203 PMCID: PMC2738614 DOI: 10.1200/jco.2008.18.1495] [Citation(s) in RCA: 233] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2008] [Accepted: 11/19/2008] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Optimal therapy of follicular lymphoma (FL) is not defined. We analyzed a large prospective cohort study to identify current demographics and patterns of care of FL in the United States. PATIENTS AND METHODS The National LymphoCare Study is a multicenter, longitudinal, observational study designed to collect information on treatment regimens and outcomes for patients with newly diagnosed FL in the United States. Patients were enrolled between 2004 and 2007. There is no study-specific prescribed treatment regimen or intervention. RESULTS Two thousand seven hundred twenty-eight subjects were enrolled at 265 sites, including the 80% of patients enrolled from nonacademic sites. Using the Follicular Lymphoma International Prognostic Index (FLIPI), three distinct groups independent of histologic grade could be defined. Initial therapeutic strategy was: observation, 17.7%; rituximab monotherapy, 13.9%; clinical trial 6.1%; radiation therapy, 5.6%; chemotherapy only, 3.2%; chemotherapy plus rituximab, 51.9%. Chemotherapy plus rituximab regimens were: rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone, 55.0%; rituximab plus cyclophosphamide, vincristine, and prednisone, 23.1%; rituximab plus fludarabine based, 15.5%; other, 6.4%. The choice to initiate therapy rather than observe was associated with age, FLIPI, stage, and grade (P < .01). Significant differences in treatment (P < .01) across regions of the United States were noted. Contrary to practice guidelines, treatment of stage I FL frequently omits radiation therapy. CONCLUSION Widely disparate therapeutic approaches are utilized for FL. Initial therapy is deferred in a small subset of patients. There is no single standard of care for the treatment of de novo FL, although antibody use is ubiquitous when therapy is initiated. These disparate approaches to the initial care of patients with FL render a heterogeneous group of patients at relapse.
Collapse
Affiliation(s)
- Jonathan W. Friedberg
- From the James P. Wilmot Cancer Center, University of Rochester, Rochester; The Leukemia & Lymphoma Society, White Plains; Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech Inc, South San Francisco, CA; Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN; Emory University, Atlanta, GA; Medical Oncology, Simon Cancer Center, Morristown, NJ; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN; Internal Medicine, Nebraska Medical Center, Omaha, NE; and Internal Medicine, University of Iowa, Iowa City, IA
| | - Michael D. Taylor
- From the James P. Wilmot Cancer Center, University of Rochester, Rochester; The Leukemia & Lymphoma Society, White Plains; Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech Inc, South San Francisco, CA; Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN; Emory University, Atlanta, GA; Medical Oncology, Simon Cancer Center, Morristown, NJ; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN; Internal Medicine, Nebraska Medical Center, Omaha, NE; and Internal Medicine, University of Iowa, Iowa City, IA
| | - James R. Cerhan
- From the James P. Wilmot Cancer Center, University of Rochester, Rochester; The Leukemia & Lymphoma Society, White Plains; Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech Inc, South San Francisco, CA; Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN; Emory University, Atlanta, GA; Medical Oncology, Simon Cancer Center, Morristown, NJ; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN; Internal Medicine, Nebraska Medical Center, Omaha, NE; and Internal Medicine, University of Iowa, Iowa City, IA
| | - Christopher R. Flowers
- From the James P. Wilmot Cancer Center, University of Rochester, Rochester; The Leukemia & Lymphoma Society, White Plains; Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech Inc, South San Francisco, CA; Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN; Emory University, Atlanta, GA; Medical Oncology, Simon Cancer Center, Morristown, NJ; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN; Internal Medicine, Nebraska Medical Center, Omaha, NE; and Internal Medicine, University of Iowa, Iowa City, IA
| | - Hildy Dillon
- From the James P. Wilmot Cancer Center, University of Rochester, Rochester; The Leukemia & Lymphoma Society, White Plains; Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech Inc, South San Francisco, CA; Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN; Emory University, Atlanta, GA; Medical Oncology, Simon Cancer Center, Morristown, NJ; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN; Internal Medicine, Nebraska Medical Center, Omaha, NE; and Internal Medicine, University of Iowa, Iowa City, IA
| | - Charles M. Farber
- From the James P. Wilmot Cancer Center, University of Rochester, Rochester; The Leukemia & Lymphoma Society, White Plains; Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech Inc, South San Francisco, CA; Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN; Emory University, Atlanta, GA; Medical Oncology, Simon Cancer Center, Morristown, NJ; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN; Internal Medicine, Nebraska Medical Center, Omaha, NE; and Internal Medicine, University of Iowa, Iowa City, IA
| | - Eric S. Rogers
- From the James P. Wilmot Cancer Center, University of Rochester, Rochester; The Leukemia & Lymphoma Society, White Plains; Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech Inc, South San Francisco, CA; Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN; Emory University, Atlanta, GA; Medical Oncology, Simon Cancer Center, Morristown, NJ; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN; Internal Medicine, Nebraska Medical Center, Omaha, NE; and Internal Medicine, University of Iowa, Iowa City, IA
| | - John D. Hainsworth
- From the James P. Wilmot Cancer Center, University of Rochester, Rochester; The Leukemia & Lymphoma Society, White Plains; Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech Inc, South San Francisco, CA; Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN; Emory University, Atlanta, GA; Medical Oncology, Simon Cancer Center, Morristown, NJ; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN; Internal Medicine, Nebraska Medical Center, Omaha, NE; and Internal Medicine, University of Iowa, Iowa City, IA
| | - Elaine K. Wong
- From the James P. Wilmot Cancer Center, University of Rochester, Rochester; The Leukemia & Lymphoma Society, White Plains; Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech Inc, South San Francisco, CA; Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN; Emory University, Atlanta, GA; Medical Oncology, Simon Cancer Center, Morristown, NJ; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN; Internal Medicine, Nebraska Medical Center, Omaha, NE; and Internal Medicine, University of Iowa, Iowa City, IA
| | - Julie M. Vose
- From the James P. Wilmot Cancer Center, University of Rochester, Rochester; The Leukemia & Lymphoma Society, White Plains; Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech Inc, South San Francisco, CA; Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN; Emory University, Atlanta, GA; Medical Oncology, Simon Cancer Center, Morristown, NJ; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN; Internal Medicine, Nebraska Medical Center, Omaha, NE; and Internal Medicine, University of Iowa, Iowa City, IA
| | - Andrew D. Zelenetz
- From the James P. Wilmot Cancer Center, University of Rochester, Rochester; The Leukemia & Lymphoma Society, White Plains; Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech Inc, South San Francisco, CA; Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN; Emory University, Atlanta, GA; Medical Oncology, Simon Cancer Center, Morristown, NJ; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN; Internal Medicine, Nebraska Medical Center, Omaha, NE; and Internal Medicine, University of Iowa, Iowa City, IA
| | - Brian K. Link
- From the James P. Wilmot Cancer Center, University of Rochester, Rochester; The Leukemia & Lymphoma Society, White Plains; Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Genentech Inc, South San Francisco, CA; Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN; Emory University, Atlanta, GA; Medical Oncology, Simon Cancer Center, Morristown, NJ; University of Wisconsin Paul P. Carbone Comprehensive Cancer Center, Madison, WI; Medical Oncology, Sarah Cannon Research Institute, Nashville, TN; Internal Medicine, Nebraska Medical Center, Omaha, NE; and Internal Medicine, University of Iowa, Iowa City, IA
| |
Collapse
|
21
|
Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study. Proc Natl Acad Sci U S A 2008; 105:10131-6. [PMID: 18645180 DOI: 10.1073/pnas.0803636105] [Citation(s) in RCA: 117] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Plant-made vaccines have been the subject of intense interest because they can be produced economically in large scale without the use of animal-derived components. Plant-made therapeutic vaccines against challenging chronic diseases, such as cancer, have received little research attention, and no previous human clinical trials have been conducted in this vaccine category. We document the feasibility of using a plant viral expression system to produce personalized (patient-specific) recombinant idiotype vaccines against follicular B cell lymphoma and the results of administering these vaccines to lymphoma patients in a phase I safety and immunogenicity clinical trial. The system allowed rapid production and recovery of idiotypic single-chain antibodies (scFv) derived from each patient's tumor and immunization of patients with their own individual therapeutic antigen. Both low and high doses of vaccines, administered alone or co-administered with the adjuvant GM-CSF, were well tolerated with no serious adverse events. A majority (>70%) of the patients developed cellular or humoral immune responses, and 47% of the patients developed antigen-specific responses. Because 15 of 16 vaccines were glycosylated in plants, this study also shows that variation in patterns of antigen glycosylation do not impair the immunogenicity or affect the safety of the vaccines. Collectively, these findings support the conclusion that plant-produced idiotype vaccines are feasible to produce, safe to administer, and a viable option for idiotype-specific immune therapy in follicular lymphoma patients.
Collapse
|
22
|
Deghiedy H, Fouda M, Shahin D, Shamaa S, El-Bedewy A, Abd El-Ghaffar H. Diagnostic and prognostic utility of t(14;18) in follicular lymphoma. Acta Haematol 2007; 118:231-6. [PMID: 18075243 DOI: 10.1159/000112474] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2007] [Accepted: 07/18/2007] [Indexed: 11/19/2022]
Abstract
BACKGROUND Follicular lymphoma (FL) is one of the most common non-Hodgkin's lymphomas of B cells, being closely associated with a t(14;18) translocation. Detection of t(14;18), which is present in 70-95% of FL, might aid in FL diagnosis. OBJECTIVE To compare the efficacy of routine polymerase chain reaction (PCR) and fluorescence in situ hybridization (FISH) techniques in detecting t(14;18) in paraffin-embedded tissue samples of FL patients at different stages. Combined with other immunophenotypic biological determinants, detection of t(14;18) might help to determine patients at increased risk according to the FL International Prognostic Index (FLIPI) and therefore facilitate appropriate treatment. DESIGN AND METHODS This study was mainly based on a retrospective examination of formalin-fixed, paraffin-embedded lymph nodes. We selected fixed tissue samples of 21 FL patients treated at the National Cancer Institute Center in the period from 2000 to 2001. RESULTS FISH techniques could detect 14 of 18 FL cases with a sensitivity of 77.8%, while the PCR technique could detect only 11 of 18 FL cases with a sensitivity of 61.1%, resulting in a statistically significant difference between both techniques (p = 0.004). According to the FLIPI index, 9 of the 18 FL patients were categorized into the high-risk group (50%), 5 in the intermediated-risk group (27.8%) and 4 in the low-risk group (22.2%). CONCLUSION The sensitivity of FISH is superior to that of PCR in the detection of the t(14;18) translocation in paraffin-embedded tissue samples. There is a statistically significant correlation between both CD10 and FISH with FLIPI.
Collapse
MESH Headings
- Adult
- Aged
- Chromosomes, Human, Pair 14/genetics
- Chromosomes, Human, Pair 14/ultrastructure
- Chromosomes, Human, Pair 18/genetics
- Chromosomes, Human, Pair 18/ultrastructure
- Female
- Gene Rearrangement, B-Lymphocyte, Heavy Chain
- Genes, Immunoglobulin
- Genes, bcl-2/genetics
- Humans
- Immunoglobulin Heavy Chains/genetics
- In Situ Hybridization, Fluorescence
- Lymph Nodes/pathology
- Lymphoma, Follicular/genetics
- Lymphoma, Follicular/mortality
- Lymphoma, Follicular/pathology
- Male
- Middle Aged
- Paraffin Embedding
- Polymerase Chain Reaction
- Prognosis
- Retrospective Studies
- Risk
- Sensitivity and Specificity
- Severity of Illness Index
- Translocation, Genetic
Collapse
Affiliation(s)
- H Deghiedy
- Hematology Unit, Clinical Pathology Department, Pathology and Oncology Center, Mansoura University, Mansoura, Egypt
| | | | | | | | | | | |
Collapse
|
23
|
Abstract
The most common low-grade non-Hodgkin lymphomas are of B-cell origin. This review will focus on follicular lymphomas and extranodal marginal zone lymphomas, also known as mucosa-associated lymphoid tissue (MALT) lymphomas. These are radiation-sensitive lymphomas. Moderate doses (30-35 Gy) for these stage I and II low-grade lymphomas result in long-term local control and possible cure. Involved-field radiation therapy is the standard approach and produces minimal morbidity. However, a significant proportion of patients relapse with systemic disease outside of radiation fields. For follicular lymphoma, this occurs in approximately 50% of patients after 15 years and for nongastric MALT lymphoma 30% to 40% after 10 years. Patients with relapsed disease are not curable with chemotherapy, but the disease often remains indolent and prolonged survival is observed. For gastric MALT lymphomas associated with Helicobacter pylori but which did not respond to antibiotic therapy, radiation treatment is indicated and almost always curative. For localized MALT lymphomas not related to microorganisms, radiation therapy is the initial standard therapy regardless of anatomic location. Patients with stage III and IV low-grade lymphoma and local symptoms are often successfully palliated with a low dose regimen of 2 x 2 Gy (total dose 4 Gy).
Collapse
Affiliation(s)
- Richard W Tsang
- Department of Radiation Oncology, University of Toronto, Princess Margaret Hospital, Toronto, Ontario, Canada.
| | | |
Collapse
|
24
|
Etto LY, Silva VC, Inaoka RJ, Costa RP, Alves AC, Colleoni GWB. Is the follicular lymphoma international prognostic index better than the international prognostic index to identify high-risk follicular lymphoma patients? Leuk Lymphoma 2007; 48:526-30. [PMID: 17454593 DOI: 10.1080/10428190601113576] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
The aims of this study are to validate follicular lymphoma international prognostic index (FLIPI) prognostic score and to compare it with the international prognostic index (IPI) in a cohort of 57 Brazilian patients. According to IPI, 24 patients (42%) were in the low-risk, 28 (49%) in the intermediate-risk, and 4 (7%) in the high-risk group. The distribution according to FLIPI was: 20 (35%) in the low-risk, 8 (14%) in the intermediate-risk, and 29 (51%) in the high-risk group. According to IPI score, median OS was not reached for the low-risk, it was 45 months for the intermediate-risk and 25 months for the high-risk group (p < 0.001). When FLIPI score was applied, median OS was not reached for the low and intermediate-risk, and was 42 months for the high-risk group (p = 0.0064). These findings suggest that: (1) FLIPI score could be validated in a Brazilian population; (2) FLIPI is more accurate than IPI to identify FL patients having worse prognosis (51%); (3) IPI seems to be a better tool for clinical decisions because it selected a smaller high-risk group (7%) having worse prognosis. In our opinion, IPI high-risk patients are the real candidates for more aggressive therapies, avoiding unnecessary over-treatment.
Collapse
|
25
|
Abstract
AbstractFollicular lymphoma constitutes the most frequent indolent lymphoma, well characterized by its clinical presentation related to nodal involvement and its morphologic and biologic features. Some rare locations of extranodal involvement, such as the gastrointestinal tract or skin, were recently further refined. The description of the Follicular Lymphoma International Prognostic Index (FLIPI) represents an important step in identifying patient subgroups with predictable outcome and comparing the results of clinical trials, although its use in clinical practice remains to be established. Analyses of gene expression profiles or constitutive gene variations may also provide additional insights for prognostication in the near future. Furthermore, these data underline the complex interactions between the tumor cells and their microenvironment; recent attempts to translate these findings with immunohistochemical studies remain unable to robustly predict patient outcome. The therapeutic strategies in follicular lymphoma have been transformed by monoclonal antibodies, used alone or in combination with chemotherapy. Treatment options should be adapted to the clinical features at diagnosis and appear to be able to modify the overall survival of some subgroups of patients. Further efforts may focus on strategies that can alter the natural history of this disease.
Collapse
|
26
|
Abstract
The observed variability in the clinical course of follicular lymphoma (FL), along with the diverse range of therapeutic options available, necessitates accurate prognostic stratification of the individual patient. A number of clinical, laboratory, and pathologic parameters have been associated with both good and poor risk disease; in some instances these have been incorporated into readily calculable prognostic indices. With new insights into disease biology and the resulting identification of biomarkers that have arisen from the analysis of both the genome and the transcriptome, more accurate individualization of prognosis will be realized. At present the clinical application of such biomarkers, however, remains largely in its infancy. This review examines the clinical and molecular prognostic features that have been identified as of value in FL.
Collapse
Affiliation(s)
- Andrew J Davies
- Department of Medical Oncology, St Bartholomew's Hospital, West Smithfield, London, UK.
| |
Collapse
|
27
|
Current Awareness in Hematological Oncology. Hematol Oncol 2006. [DOI: 10.1002/hon.753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|